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Abstract: Clinical evidence indicates that innate immune cells may contribute to acute coronary
syndrome (ACS). Our prospective study aimed at investigating the association of neutrophil
phenotypes with ACS. 108 patients were categorized into chronic stable coronary artery disease
(n = 37), unstable angina (UA) (n = 19), Non-ST-Elevation Myocardial Infarction (NSTEMI) (n = 25),
and ST-Elevation Myocardial Infarction (STEMI) (n = 27). At the time of inclusion, blood neutrophil
subpopulations were analysed by flow cytometry. Differential blood cell count and plasma
levels of neutrophilic soluble markers were recorded at admission and, for half of patients,
at six-month follow-up. STEMI and NSTEMI patients displayed higher neutrophil count and
neutrophil-to-lymphocyte ratio than stable and UA patients (p < 0.0001), which normalized at
six-month post-MI. Atypical low-density neutrophils were detected in the blood of the four patient
groups. STEMI patients were characterized by elevated percentages of band cells compared to the
other patients (p = 0.019). Multivariable logistic regression analysis revealed that plasma levels of
total myeloperoxidase was associated with STEMI compared to stable (OR: 1.434; 95% CI: 1.119–1.837;
P < 0.0001), UA (1.47; 1.146–1.886; p = 0.002), and NSTEMI (1.213; 1.1–1.134; p = 0.0001) patients,
while increased neutrophil side scatter (SSC) signal intensity was associated with NSTEMI compared
to stable patients (3.828; 1.033–14.184; p = 0.045). Hence, changes in neutrophil phenotype are
concomitant to ACS.
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1. Introduction
Increasing clinical evidence supports the existence of a link between low-grade systemic
inflammation and cardiovascular (CV) risk [1]. Plasma level of high-sensitive C-reactive protein
(hs-CRP) at the time of acute coronary syndrome (ACS) and its rise after the incident disease have
been associated with a higher risk of major CV event [2]. CRP is produced by the liver in response
to elevation of pro-inflammatory cytokines such as IL-6 and IL-1β, two well-recognized players in
atherosclerosis progression. In the CANTOS trial [3], dampening inflammation by targeting the IL-1β
pathway at the time of ACS lowered the risk of recurrent major CV events in patients who experienced
a previous ACS. Hence, inflammation is currently considered as a modifiable CV risk factor. Among
other inflammation-related risk factors, several studies pointed to the differential white blood cell
count, with a particular focus on neutrophils, lymphocytes and monocytes. Neutrophil count by itself
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could predict both acute and chronic CVD [4,5]. Interestingly, an elevated neutrophil-to-lymphocyte
ratio (NLR) has not only been associated with CVD but also with short-term adverse CVD outcomes,
including mortality, coronary artery disease (CAD), stroke and heart failure [6]. Changes in NLR are
subsequent to a modification of the balance between innate (neutrophils) and adaptive (lymphocytes)
immunity. The association between elevated NLR and poor prognosis in cancer has also been linked to
cancer-elicited release of immune suppressive neutrophils from the bone marrow [7–9]. In view of
recent reports on the existence of common risk factors in CVD and cancer [10], it is therefore possible
that CVD might similarly be associated with a mobilisation of neutrophils with altered phenotype,
which might contribute to ACS risk. In chronic inflammatory diseases, as in cancer, peripheral blood
neutrophils display diversity in their phenotype [8]. To date, neutrophil phenotypes in CAD patients
and their association with ACS risk and outcome remain unexplored. Our study aimed at providing a
first description of neutrophil phenotypes in prospectively recruited coronary artery disease patients.
We investigated the association of neutrophil markers with ACS, their evolution after six months,
as well as their capability to predict patient outcome during one-year follow-up.
2. Materials and Methods
2.1. Patients and Study Design
A total of 124 patients admitted to our cardiac catheterization lab at University of Liège Hospital
were prospectively recruited between March 2017 and October 2018 (Figure 1). Patients were classified
as chronic stable coronary artery disease (angina symptoms/brief discomfort during exertion or
physiological stress and with significant coronary lesions), unstable angina (UA, recent onset or
worsening angina for up to two months, or resting angina, with or without electrocardiographic
changes and significant coronary lesions), Non-ST-Elevation Myocardial Infarction (NSTEMI, troponin
elevation above the 99-percentile associated with symptoms compatible with myocardial ischemia
without significant elevation of the ST segment), and ST-Elevation Myocardial Infarction (STEMI,
troponin elevation above the 99-percentile associated with symptoms consistent with myocardial
ischemia with significant ST segment elevation). Patients who displayed angiographically healthy
coronary arteries, myocardial infarction (MI) with nonobstructive coronary arteries (MINOCA),
Takotsubo syndrome, spontaneous coronary artery dissection, myocarditis and pericarditis or those
who did not sign the inform consent were excluded (16 patients out of 124). Patient demographic and
clinical characteristics were recorded at admission. Biological variables were measured at admission
and after > six months for a subset of patients (47%). The study was conducted according to the
Declaration of Helsinki principles upon approval by the ethical committee of the University of Liège
Hospital (B70720097066; 2009/205, accepted 11/24/2009).
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Figure 1. Study flow chart. CAD, coronary artery disease; FC, flow cytometry; NLR, neutrophil-to-
lymphocyte ratio; NSTEMI, Non-ST-Elevation Myocardial Infarction; STEMI, Non-ST-Elevation
Myocardial Infarction; UA, unstable angina.
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2.2. Blood Samples, Sera and Platelet Poor Plasma (PPP) Preparation, Laboratory Measurements
Blood samples from patients were collected from radial or femoral site of arterial catheter and
processed within 1 h. Blood samples were always obtained around midday to limit circadian oscillations
of neutrophil phenotypes. Haematological parameters were determined in EDTA-anticoagulated
blood on a Cell-Dyn 3700 (Abbott Laboratories). Platelet poor plasma was obtained after two
consecutive centrifugations at 1750 g during 15 min at room temperature. Sera were obtained following
one centrifugation at 1750 g during 15 min at RT. Plasma and sera were stored at −80 ◦C until
analysis. IL-6 and S100A9 were measured on EDTA-plasma using a Luminex assay kit (R&D Systems,
Minneapolis, MN, USA) according to the manufacturer’s instructions. Nucleosome levels were
quantified on EDTA-plasma with the Cell Death Detection ELISA plus kit (Sigma-Aldrich, Overijse,
Belgium). Myeloperoxidase quantity and activity were analysed on EDTA-plasma by a method adapted
from Franck et al. [11] using a human myeloperoxidase (MPO) Quantikine ELISA kit (R&D Systems).
hs-CRP, CK-MB (Abbott Laboratories, Wavre, Belgium) and high-sensitive troponin T (hs-TnT) (Roche,
Machelen, Belgium) were measured in sera by routine immunoassays.
2.3. Normal and Low-Density Neutrophil Phenotyping
Low density neutrophils (LDNs) and normal density neutrophils (HDNs) were separated
from EDTA-anticoagulated blood by density gradient centrifugation (Ficoll-Paque, GE Healthcare)
under endotoxin-free conditions. The peripheral blood mononuclear cell (PBMC) fraction contains
LDNs and the granulocyte fraction contains HDNs. LDNs and HDNs were phenotyped by flow
cytometry using a panel of antibodies directed against CD45 (clone HI30, BD Biosciences), CD66b
(clone G10F5, BioLegend), CD11b (clone ICRF44, BD Biosciences), CD16 (clone 3G8, BD Biosciences)
and CD10 (clone HI10a, BioLegend) as previously described [12]. The gating strategy is shown
in supplemental Figure S1. Data were acquired on a FACSVerse cytometer and analysed with the
FACSuite software (BD Biosciences). Data included levels of CD11b, CD16 and CD10 expressed on
the surface of CD66b positive LDNs and HDNs as well as percentages of neutrophils at different
maturation stages in these two cell populations, e.g., segmented cells (CD10+CD16+CD11b+/high),
band cells (CD10−/lowCD16intCD11b+), metamyelocytes (CD10−CD16lowCD11b+), myelocytes
(CD10−CD16−CD11blow), and promyelocytes (CD10−CD16−CD11b−). Cytospins of LDNs and HDNs
were performed after positive cell selection by magnetic bead cell sorting (MACS Miltenyi Biotech)
using an anti-CD66b antibody (clone G10F5, BioLegend) according to the manufacturer’s instructions.
2.4. Statistics
Qualitative variables are summarized as numbers and percentages. Normality of the distribution of
quantitative variables was tested by Shapiro-Wilk test. Quantitative variables with normal distribution
were presented as mean ± SD, while median (interquartile range (p25–p75)) were reported for
quantitative variables with skewed distribution. Qualitative characteristics of patient groups were
compared by Chi-square or Fisher exact tests. ANOVA or Kruskal-Wallis tests were applied for
quantitative variables as appropriate, with Tukey or DSCF post-hoc test, respectively. Spearman
correlation analyses were performed to assess the association between LDN percentage and other
quantitative variables. Multinomial logistic regression (MLR) was applied to model association between
CAD categories and demographic, clinical and biological variables. Significant variables with p < 0.1
after univariate MLR analyses were considered into multivariable MLR analysis [13]. Results of
the final MLR model were presented using odds ratios and corresponding 95% confidence interval.
Cox proportional hazard models were used to investigate the occurrence of composite endpoint
at 1-year follow-up (cardiovascular death, stroke, myocardial infarction or major bleeding) and to
evaluate the prognostic value of changes in neutrophil markers from baseline to 6-month follow-up.
Multivariable Cox model for composite endpoint at 1-year follow-up used the same variable selection
method as for MLR. All hazard ratios (HR) were calculated with appropriate unit and corresponding
95% confidence interval. Concordance index (c-index) of the final model was calculated following
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Uno’s method and is presented as c-index with interquartile range (IQR). All tests were performed
2-sided and p < 0.05 was considered significant except when specified. Statistical analyses were
performed using SAS 9.4 (SAS Institute, Tervuren, Belgium).
3. Results
3.1. Patient Characteristics, Inflammatory and Conventional Neutrophil Markers
A total of 108 patients were included: 37 (34%) patients had chronic stable coronary artery
disease (stable), 19 (18%) UA, 25 (23%) NSTEMI, and 27 (25%) STEMI. Patient demographic and
clinical characteristics according to diagnosis are depicted in Table 1. Patients from the four categories
did not differ in terms of age, sex and conventional CVD risk factors. However, differences were
observed in regard to aspirin (p = 0.0005) and lipid-lowering therapy (p = 0.001). Triglyceride levels
were more elevated in STEMI patients than in UA (p = 0.009) and NSTEMI (p = 0.006). Regarding
systemic inflammatory markers, the four patient groups displayed different levels of IL-6 (p = 0.003)
(Table 2). As expected, differences in differential white blood cell counts were observed, mostly
related to changes in neutrophil count. NSTEMI and STEMI patients had higher neutrophil counts
than stable and UA patients (p < 0.0001; NSTEMI vs. UA p = 0.012). Among ACS, NSTEMI patients
showed higher monocyte count than stable patients (p < 0.0001). In contrast, lymphocyte counts
did not differ between patient categories. However, changes in NLR likely reflected the increase of
neutrophil count. Plasma levels of S100A9, total and active MPO, and of nucleosomes, well-known
circulating markers of neutrophil activation and neutrophil extracellular trap (NET) release that have
previously been associated with CVD risk and ACS [14–17], were higher in STEMI patients than in
stable (S100A9: p = 0.013; total MPO: p < 0.0001; active MPO: p < 0.0001; nucleosomes: p = 0.032) and
UA (S100A9: p = 0.018; total MPO: p < 0.0001; active MPO: p < 0.0001; nucleosomes: p = 0.007) patients
(Figure 2A). Despite similar increase of neutrophil count in NSTEMI and STEMI patients, the levels
of these neutrophil markers were not significantly more elevated in NSTEMI patients than in stable
and UA, suggesting that neutrophil phenotype, in addition to absolute cell numbers, differed between
STEMI and other ACS conditions. Accordingly, total and active MPO levels were more elevated in
STEMI than in NSTEMI patients (p < 0.0001) (Figure 2A).
Table 1. Patient characteristics according to coronary artery disease (CAD) category.
Stable n = 37 UA n = 19 NSTEMI n = 25 STEMI n = 27 p
Age (yrs) 69 ± 9 67 ± 11 63 ± 12 64 ± 10 0.081
Male gender, n (%) 25 (67.6) 17 (89.5) 19 (76) 20 (74.1) 0.356
Smoking, n (%) 24 (64.9) 12 (63.2) 15 (60) 22 (81.5) 0.343
Body mass index 27.8 (25.3–31.0) 28.7 (24.6–34.3) 26.8 (25.4–29.7) 26.9 (24.2–31.0) 0.616
Hypertension, n (%) 29 (78.4) 16 (84.2) 14 (56) 18 (66.7) 0.133
Hypercholesterolemia, n
(%) 25 (67.6) 13 (68.4) 13 (52) 13 (48.1) 0.302
Diabetes, n (%) 13 (35.1) 8 (42.1) 5 (20) 8 (29.6) 0.425
Chronic renal failure, n (%) 5 (13.5) 3 (15.8) 1 (4) 4 (14.8) 0.530
Chronic inflammatory
disease, n (%) 7 (18.9) 2 (10.5) 0 (0) 4 (14.8) 0.107
Active cancer, n (%) 0 (0) 2 (10.5) 2 (8) 4 (14.8) 0.069
History of DVT, n (%) 2 (5.4) 1 (5.3) 0 (0) 2 (7.4) 0.669
History of stroke, n (%) 4 (10.8) 2 (10.5) 0 (0) 0 (0) 0.086
History of MI, n (%) 11 (29.7) 4 (21.1) 1 (4) 7 (25.9) 0.095
History of CABG, n (%) 6 (16.2) 2 (10.5) 3 (12) 1 (3.7) 0.475
History of PCI, n (%) 12 (32.4) 10 (52.6) 5 (20) 8 (29.6) 0.145
Aspirin, n (%) 31 (83.8) 15 (78.9) 9 (36) 15 (55.6) 0.0005
DAPT, n (%) 5 (13.5) 1 (5.3) 3 (12) 3 (11.1) 0.886
Anticoagulant, n (%) 1 (2.7) 1 (5.3) 0 (0) 1 (3.7) 0.878
Lipid-lowering drug, n (%) 28 (75.7) 14 (73.7) 8 (32) 12 (44.4) 0.001
hs-cTnT (ng/L) 13 (8–23) 16 (10–20) 689 (303–1304) a,b 293 (19–1438) a,b <0.0001
CK-MB (µg/L) 2.80 (2.00–4.50) 2.50 (1.80–3.50) 22.50 (14.80-60.00) a,b 4.94 (2.50–47.56) a,b <0.0001
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Table 1. Cont.
Stable n = 37 UA n = 19 NSTEMI n = 25 STEMI n = 27 p
Creatinine (mg/dL) 1.08 (0.90–1.30) 1.00 (0.88–1.23) 0.94 (0.81–1.09) 0.95 (0.86–1.13) 0.207
Total cholesterol (mg/dL) 155 (138–181) 142 (126–208) 170 (143–211) 181 (142–195) 0.299
LDL (mg/dL) 87 (68–106) 78 (72–127) 109 (91–137) 111 (73–143) 0.052
HDL (mg/dL) 44 (36–53) 35 (29–45) 39 (34–48) 39 (34–49) 0.162
Triglycerides (mg/dL) 113 (88–180) 139 (100–197) 136 (101–165) 82 (62–114) b,c 0.003
Apo A-I (g/dL) 1.32 (1.11–1.48) 1.14 (1.03–1.40) 1.29 (1.14–1.44) 1.21 (1.08–1.40) 0.497
Apo B (g/dL) 0.77 (0.61–0.90) 0.79 (0.74–1.05) 0.95 (0.85–1.08) 0.91 (0.70–1.07) 0.081
Lipoprotein (a) (nmol/L) 15 (8–70) 35 (10–118) 33 (10–135) 25 (9–116) 0.727
PCSK9 (pg/mL) 45514 (29768–85118) 55279 (23275–74669) 58512 (27008–78619) 76762 (33957–127092) 0.307
Abbreviations: Apo A-I, apolipoprotein A-I; Apo B, apolipoprotein B; CABG, coronary artery bypass grafting;
CK-MB, creatine kinase-myocardial band; DAPT, dual antiplatelet therapy; DVT, deep venous thrombosis; HDL,
high density lipoprotein; hs-cTnT, high sensitivity cardiac troponin T; LDL, low density lipoprotein; MI, myocardial
infarction; PCI, percutaneous coronary intervention. Continuous data are presented as median (IQR). a indicates
p < 0.05 vs. stable; b p < 0.05 vs. UA; c p < 0.05 vs. NSTEMI; d p < 0.05 vs. STEMI.
Table 2. Haematological and inflammatory parameters according to patient category.
Stable n = 37 UA n = 19 NSTEMI n = 25 STEMI n = 27 p
Lymphocyte count (1000/µL) 1.41 (1.06–1.77) 1.82 (0.95–2.24) 1.79 (1.39–2.20) 1.54 (1.20-2.13) 0.185
Monocyte count (1000/µL) 0.46 (0.33–0.58) 0.53 (0.39–0.76) 0.73 (0.59–0.92) a 0.64 (0.46-0.86) <0.0001
Neutrophil count (1000/µL) 3.0 (2.1–4.5) 3.9 (2.5–5.2) 5.8 (4.6–8.3) a,b 7.4 (6.4-9.7) a,b <0.0001
Eosinophil count (1000/µL) 0.12 (0.06–0.25) 0.12 (0.05–0.24) 0.06 (0.04–0.13) 0.07 (0.04-0.13) 0.094
Basophil count (1000/µL) 0.05 (0.04–0.08) 0.06 (0.04–0.07) 0.06 (0.04–0.08) 0.06 (0.04–0.07) 0.98
Haematocrit (%) 42 (41–47) 44 (41–48) 45 (42–48) 42 (38–47) 0.346
Platelet count (1000/µL) 255 ± 71 243 ± 63 247 ± 81 279 ± 72 0.309
Mean platelet volume (fL) 7.8 (7.4–8.3) 7.8 (7.6–8.8) 7.8 (7.1–8.3) 7.6 (7.0–8.5) 0.455
NLR 2.3 (1.8–3.2) 2.2 (1.7–3.1) 3.7 (2.3–5.3) a 4.9 (2.7–7.5) a,b <0.0001
PLR 157 (141–244) 138 (112–239) 144 (119–170) 174 (122–209) 0.212
hs-CRP (mg/L) 2.93 (0.84–6.87) 1.26 (0.58–4.51) 6.09 (2.62–19.55) 2.51 (0.68–13.22) 0.082
IL-6 (pg/mL) 1.7 (0.4–3.4) 0.7 (0.2–1.5) 2.8 (0.9–13.0) 3.0 (0.8–12.3) 0.033
S100A9 (pg/mL) 213 (142–399) 250 (126–361) 273 (213–466) 431 (292–621) a,b 0.008
Active MPO (ng/mL) 1.5 (1.2–3.2) 1.4 (1.1–1.9) 2.0 (1.5–3.2) 8.4 (4.9–13.2) a,b,c <0.0001
Total MPO (ng/mL) 4.1 (2.9–7.2) 3.7 (2.6–5.5) 5.7 (4.1–8.1) 23.6 (18.6–27.0) a,b,c <0.0001
Nucleosomes (AU) 0.04 (0.02–0.11) 0.03 (0.02–0.06) 0.06 (0.04–0.15) 0.09 (0.05–0.22) a,b 0.006
Abbreviations: hs-CRP, high-sensitivity C-reactive protein; MPO, myeloperoxidase; NLR, neutrophil-to-lymphocyte
ratio; PLR, platelet-to-lymphocyte ratio. Data are presented as mean±SD or median (IQR). a indicates p < 0.05 vs.
stable; b p < 0.05 vs. UA; c p < 0.05 vs. NSTEMI; d p < 0.05 vs. STEMI.
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Figure 2. Neutrophil markers according to CAD category. (A) Plasma MPO levels. (B) Side scatter
(SSC) signal intensity of high-density neutrophils (HDN) as determined by flow cytometry on blood
granulocytic fraction. (C) Percentage of band cells in low-density neutrophils (LDN) isolated from
peripheral blood mononuclear fraction. Data are presented using Tukey outlier box plots with box
limits representing IQR and median in the middle, whiskers’ length are equal to 1.5 times of IQR.
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3.2. Neutrophil Phenotypes in ACS
A detailed phenotypic analysis of neutrophils was performed for the four patient groups.
We detected low percentages of LDNs in the peripheral blood mononuclear cells (PBMC) fraction
isolated from patient blood, which were not different between patient groups (stable: 0.86 [0.36–1.8];
UA: 0.88 [0.39–1.77]; NSTEMI: 0.95 [0.38–2.1]; STEMI: 1.53 [0.57–6.69], p = 0.272). LDNs represented
a heterogeneous cell population comprising variable proportions of myelocytes, band cells and
segmented cells (Table S1). LDNs displayed features of immature cells, e.g., they were larger and
expressed lower levels of CD11b, CD10 and CD16 than HDNs (Figure S2). The LDN percentage
showed a modest correlation with the NLR (r = 0.32, p = 0.01), while it was not influenced by any other
patients’ characteristics. Interestingly, STEMI patients were characterized by elevated percentages of
band cells (CD10−/lowCD16intCD11b+) in LDNs compared to the three other patient groups (p = 0.007)
(Figure 2C, Figure 3A, and Table 3). Few band cells were detected in HDN fraction, with again higher
percentages in the blood from STEMI patients than in stable (p = 0.047) and UA (p = 0.006) patients
(Figure 2B–D and Table 1). HDNs from NSTEMI patients displayed higher complexity than those from
stable (p = 0.003) and UA (p = 0.031) patients, as determined by SSC (side scatter) signal intensity
(Table 1) (Figure 2B). There were no significant differences in CD11b, CD16 or CD10 expression levels
on the surface of HDNs or LDNs from the four patient groups. Altogether, these data indicate that the
increase of neutrophil count in ACS likely reflects elevated numbers of circulating neutrophils of high
density. Distinct phenotypic neutrophil features were identified in STEMI and NSTEMI ACS. Elevated
numbers of band cells were detected in the blood from STEMI patients, while NSTEMI patients were
characterized by the presence of high-complexity HDNs.
Table 3. Neutrophil phenotype according to patient category.
















CD11b (MFI) 12,108 ± 4070 12,236 ± 4527 13,798 ± 4300 14,150 ± 3541 0.215








Band cells (%) 0.03 (0.01–0.08) 0.01 (0.00–0.06) 0.02 (0.01–0.09) 0.11 (0.03–0.36) a,b 0.019
LDN
% in PBMC 0.86 (0.36–1.80) 0.88 (0.39–1.77) 0.95 (0.38–2.10) 1.53 (0.57–6.69) 0.272
Band cells (%) 2.5 (1.2–6.8) 2.7 (1.0–6.5) 2.7 (1.8–7.3) 9.5 (4.0–13.7) a,b,c 0.007
Abbreviations: HDN, normal density neutrophil; LDN, low density neutrophil; MFI, median intensity of fluorescence;
PBMC, peripheral blood mononuclear cells; SSC, side scatter; FSC, forward scatter. Data are presented as mean ± SD
or median (IQR). a indicates p < 0.05 vs. stable; b p < 0.05 vs. UA; c p < 0.05 vs. NSTEMI; d p < 0.05 vs. STEMI.
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Figure 3. Neutrophil phenotype in the blood of NSTEMI and STEMI patients. (A) CD66b+ low density
neutrophils (LDNs) from peripheral blood mononuclear cell (PBMC) fraction of STEMI patient blood.
(B) and (C). CD66b+ high density neutrophils (HDNs) from the granulocytic (GN) fraction of STEMI
and NSTEMI patient blood. Representative flow cytometry plots are shown depicting our phenotyping
strategy (see Methods section for details). The red frame corresponds to band cells, represented in
red on dot plots. Upper left panels represent cytospin images of sorted CD66b+ cells. Segmented
cells (black arrowheads), larger segmented cells (yellow arrowhead), band cells (*) myelocytes (**).
Bars represent 10 µm.
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3.3. Neutrophil Markers in ACS
The association of these neutrophil markers with the four patient groups was assessed.
After adjustment with confounding variables, i.e., age, gender, daily low-dose aspirin, and
lipid-lowering therapy, plasma levels of total MPO (p < 0.0001), HDN SSC (p = 0.026) and hs-cTnT
(p = 0.015) were independently associated with the four patient groups (Table 4). Plasma levels
of total MPO were associated with STEMI compared to stable (OR per 1-ng/mL increase, 1.434;
95% CI, 1.119–1.837; p < 0.0001), UA (OR per 1-ng/mL increase, 1.47; 95% CI, 1.146–1.886; p = 0.002),
and NSTEMI (OR per 1-ng/mL increase, 1.213; 95% CI, 1.1–1.1338; p = 0.0001) patients. Increased SSC
intensity was associated with NSTEMI compared to stable (OR per 10000-MFI increase, 3.828; 95% CI,
1.033–14.184; p = 0.045).
Table 4. Multivariable multinomial logistic regression model for CAD category *.
Variable Comparison Unit Odds Ratio (95% CI) p
hs-cTnT (ng/L) NSTEMI vs. Stable 10 1.062 (1.020–1.105) 0.003
STEMI vs. Stable 10 1.061 (1.019–1.104) 0.004
Unstable vs. Stable 10 0.953 (0.824–1.103) 0.288
NSTEMI vs. Unstable 10 1.114 (0.961–1.291) 0.152
STEMI vs. Unstable 10 1.113 (0.960-1.290) 0.156
NSTEMI vs. STEMI 10 0.999 (0.994–1.004) 0.722
Total MPO (ng/mL) NSTEMI vs. Stable 1 1.182 (0.919–1.519) 0.193
STEMI vs. Stable 1 1.434 (1.119–1.837) <0.0001
Unstable vs. Stable 1 0.975 (0.857–1.11) 0.703
NSTEMI vs. Unstable 1 1.212 (0.942–1.559) 0.135
STEMI vs. Unstable 1 1.47 (1.146–1.886) 0.002
STEMI vs. NSTEMI 1 1.213 (1.100–1.338) 0.0001
HDN SSC NSTEMI vs. Stable 10000 3.828 (1.033–14.184) 0.045
STEMI vs. Stable 10000 3.029 (0.899–10.202) 0.074
Unstable vs. Stable 10000 1.101 (0.603–2.007) 0.755
NSTEMI vs. Unstable 10000 3.478 (0.990–12.217) 0.052
STEMI vs. Unstable 10000 2.752 (0.843–8.977) 0.094
STEMI vs. NSTEMI 10000 0.791 (0.423–1.478) 0.462
* Adjusted for age, sex, daily low-dose aspirin, lipid-lowering therapy. Abbreviations: HDN, normal density
neutrophil; hs-cTnT, high-sensitive cardiac troponin T; MPO, myeloperoxidase; SSC, side scatter. Comparisons with
p values < 0.05 are shown in italics.
Total MPO levels correlated with neutrophil count (r = 0.43, p = 0.0003) and levels of nucleosomes
(r = 0.53, p < 0.0001). A moderate correlation was observed with S100A9 levels (r = 0.38, p = 0.0003),
NLR (r = 0.30, p = 0.006), hs-TnT (r = 0.34, p = 0.002) and CK-MB (r = 0.24, p = 0.022). MPO levels were
not influenced by any other patient characteristics or medication. HDN SSC showed a strong positive
significant correlation with HDN FSC (r = 0.72, p < 0.0001) only.
3.4. Evolution of Neutrophil Markers during Follow-Up
To assess time-dependent changes in neutrophil markers and to determine whether changes
concomitant to myocardial injury were maintained at distance of ACS, some of these markers
were measured after six months post-admission. Data could be obtained for 51 patients from the
four categories (18 stable, 11 UA, 11 STEMI, 11 NSTEMI). Baseline characteristics of patients from
this subgroup are shown in supplementary Table S2. Although neutrophil count (p < 0.0001),
NLR (p = 0.0004) and MPO levels (p = 0.0009) and activity (p = 0.0002) differed between ACS and stable
or UA patients at admission, these markers no longer differed between these patient groups at follow-up
(Table S3). Likewise, stable patients who had a previous myocardial infarction (11 patients out of 37)
did not differ in any neutrophil markers, i.e., NLR, MPO levels, LDN and band cell percentages,
and HDN SSC (Table S4). These data suggest that mobilization of neutrophils harbouring a specific
phenotype likely occurs at the time of myocardial infarction, which globally resolves over time.
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4. Discussion
Despite advances in understanding atherosclerotic processes, progression of CAD to acute events
remains poorly understood and hardly possible to predict. Several studies indicate that neutrophils are
involved in plaque progression [18–21], and preclinical data in mice suggest that low-grade systemic
inflammation could promote atherosclerosis progression through neutrophil reprogramming [22].
Our study provides first clinical evidence that phenotypic modifications of circulating neutrophils
occur around the time of MI. Moreover, our data suggest that these neutrophil phenotypes normalize
with time. In addition, differences in neutrophil phenotypes were observed between STEMI and
NSTEMI patients.
4.1. Neutrophil Phenotypes in ACS
In CVD, it has been hypothesized that the NLR could reflect the release of immune suppressor cells
(e.g., granulocytic myeloid suppressor cells, G-MDSC) from the bone marrow. In cancer and in various
chronic diseases, G-MDSC can be isolated from the LDN neutrophil subset [23,24]. We identified
variable percentages of LDN in the PBMC fraction of CAD patients’ blood, irrespective of disease stage.
We showed too that neutrophils with altered phenotype circulate in the blood of STEMI and NSTEMI
patients. We identified immature band cells in HDN and LDN from STEMI patient blood, while HDNs
with high complexity were observed in the blood from NSTEMI patients. Circulating neutrophils
from NSTEMI patients may therefore have distinct functionality and granular content. Band cells are
neutrophils at intermediary stage of maturation, characterized by a curved nucleus. The appearance of
these immature cells in the blood results from signals to the bone marrow for increased neutrophil
production, as in the case of infection or inflammation. In STEMI, this probably indicates a response
to severe myocardial damage with a high demand for neutrophils. Our observation that the LDN
percentage moderately correlates with NLR could suggest an important biological role of these cells
that might be independent of inflammation and conventional CV risk factors. In chronic inflammatory
diseases such as lupus erythematous or psoriasis, low-density granulocytes that are more prone to
produce NETs are thought to contribute to higher CVD risk [25,26]. For instance, the frequency of these
cells has been associated with non-calcified coronary plaque burden in patients with psoriasis [27].
Whether LDNs from CAD patients possess immune suppressive or pro-inflammatory function or
whether they are more susceptible to release NETs remains to be determined.
4.2. Soluble Neutrophil Markers in ACS
We found elevated levels of soluble neutrophil activation markers, including MPO, S100A9 and
nucleosomes in STEMI but not in NSTEMI patients, and this despite similar rise in neutrophil count
and NLR. Total MPO levels appeared as a strong independent marker of STEMI. These distinct features
between NSTEMI and STEMI might reflect different pathophysiological mechanisms leading to these
ACS entities, which could not be picked up based on neutrophil count or NLR only. Noteworthy,
it has recently been recognized that beside differences in ECG and troponin levels, plaque composition
as well as mechanisms of atherogenesis influence CAD patient outcome [28–30]. MPO, stored in
neutrophil azurophilic granules, is released upon neutrophil activation. Increased circulating levels of
this protein have already been shown to predict the outcome of patients with ACS [15,16]. MPO would
also be a marker of plaque vulnerability [16]. Interestingly, it has been reported that higher circulating
MPO levels were found in ACS patients with culprit plaque erosion than in those with culprit plaque
rupture [31]. It is noteworthy that in agreement with the study by Ferrante et al. [31], we did not
find any correlation between MPO levels and markers of systemic inflammation, CRP or IL-6, while
correlations were observed with other neutrophil-derived markers, like S100A9 and nucleosomes.
Hence, neutrophil markers are likely to carry additional information compared to classical inflammatory
markers since they may underlie biological mechanisms leading to ACS.
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4.3. Neutrophil Dynamics after ACS
In the study by Kim et al. [6], the shorter median time from ACS improved the strength of the
association of NLR with a subsequent adverse event. Therefore, it has been suggested that the NLR
would increase over time in CVD patients and reach a maximum around the time of event. In our
study, in a subset of patients from each category, we could evaluate differential blood cell count,
soluble neutrophil markers and inflammation at six-months post-MI. We showed that neutrophil count,
NLR and soluble neutrophil markers returned to levels of stable patients during the follow-up period,
therefore confirming that these markers reach a maximum around the time of ACS.
4.4. Clinical Implications
Our study highlights potential roles for neutrophil phenotypes as novel biomarkers in CAD.
Advances in the cellular biology of atherosclerosis and its pathogenesis have led to major advances in its
treatment. We provide first evidence that neutrophils could be a key player in the disease progression
to ACS through changes in their phenotype and secretory profiles. Targeting pro-inflammatory or
immune regulatory neutrophils (specific neutrophil subsets) and/or their downstream mediators that
promote adverse effects (e.g., NET, pro-inflammatory cytokines, reactive nitrogen/oxygen species,
neutrophil serine proteases, danger-associated molecular pattern molecules) may thus represent new
therapeutic opportunities. Deoxyribonuclease (DNAse), an enzyme that breaks down NET, has been
shown in a clinical study of STEMI patients to accelerate lysis of coronary thrombi [32]. Colchicine,
an anti-inflammatory agent, has been shown to acutely suppress caspase-1 activity and inhibit
inflammasome related cytokines in monocytes from ACS patients [33]. The use of colchicine in patients
with recent myocardial infarction was also effective in reducing CV events [34]. Serine proteases
liberated from activated neutrophils, e.g., cathepsin G, elastase, proteinase-3, are potent regulators
of at least six IL-1 cytokine family members, including IL-1β [35]. One might consider inhibiting
these extracellular proteases since this strategy will not affect neutrophil antimicrobial capability [35].
Neutrophils may indeed represent a major source of IL-1β in ACS. In cancer, IL-1β and S100A9 have
been involved in the mobilization of pro-tumoral immature neutrophils with immune suppressive
functions [36,37]. These molecules might also contribute to the production of immune suppressive
neutrophils at the time of ACS. Neutrophils might also contribute to pathological oxidative stress,
thereby altering the regulation of coronary blood flow by cardiac metabolism as seen in diabetes
mellitus [38,39]. Hence, our study may pave the way toward new therapeutic avenues in ACS.
4.5. Limitations
The number of patients examined may be perceived as low. Nevertheless, our study of neutrophil
profiles is unique, as it required good logistics coordination, involving both the laboratory and the
clinics. Neutrophils need to be processed in a highly standardized manner within one-hour after blood
collection. Blood samples were only obtained during working days. The neutrophil profile during
follow-up was obtained in only half of the patients. Given the distinct function of each neutrophil
subpopulation, it is likely that each subset participates in various pathophysiological mechanisms
of CAD. The relationship between the neutrophil phenotypes and neutrophil function has not been
studied. The relationship between neutrophil phenotype and scores of CAD severity has not been
analysed. In addition, our study does not bring out a causal link between the neutrophilic profile and
the destabilization of the coronary disease. It must be considered hypothesis-generating, even if the
secretory and morphological dynamics of neutrophils are suggestive. Future larger studies evaluating
the role of neutrophils in ACS onset and outcome are needed.
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5. Conclusions
Our study indicates that, in patients with CAD, changes in neutrophil phenotypes occur
concomitantly to ACS. These changes may reflect different acute complications of CAD and reveal new
biological processes leading to ACS.
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